NATCOPHARM.BONATCOPHARM.BOBSE
Loading
Year-over-year SG&A expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P44
Within normal range
Average
5.19%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | 16.60% |
| Q4 2024 | -6.53% |
| Q3 2024 | 6.69% |
| Q2 2024 | -7.49% |
| Q1 2024 | 25.92% |
| Q4 2023 | -0.41% |
| Q3 2023 | -11.43% |
| Q2 2023 | 2.67% |
| Q1 2023 | 27.46% |
| Q4 2022 | -4.26% |
| Q3 2022 | -10.18% |
| Q2 2022 | -25.58% |
| Q1 2022 | 39.59% |
| Q4 2021 | 8.24% |
| Q3 2021 | 1.02% |
| Q2 2021 | -17.10% |
| Q1 2021 | 28.60% |
| Q4 2020 | -18.03% |
| Q3 2020 | 29.94% |
| Q2 2020 | -48.26% |
| Q1 2020 | 88.14% |
| Q4 2019 | -4.49% |
| Q3 2019 | 9.87% |
| Q2 2019 | -45.81% |
| Q1 2019 | 84.35% |
| Q4 2018 | 0.76% |
| Q3 2018 | 4.40% |
| Q2 2018 | -29.99% |
| Q1 2018 | 60.79% |
| Q4 2017 | 5.35% |
| Q3 2017 | 18.54% |
| Q2 2017 | -41.93% |
| Q1 2017 | 94.05% |
| Q4 2016 | -7.32% |
| Q3 2016 | 21.37% |
| Q2 2016 | -19.12% |
| Q1 2016 | 31.10% |